© 2025 MJH Life Sciences™ and Patient Care Online. All rights reserved.
Grace Halsey
Articles
CagriSema Phase 3 Update: Weight Loss of Nearly 16% Seen in REDEFINE 2 Trial
March 11, 2025
CagriSema proved superior to placebo in the pivotal phase 3 trial but as in the earlier REDEFINE 1 study fell short of the 25% or greater reduction Novo Nordisk projected.
For Atopic Dermatitis, "The Treatment Drought is Over," Says Expert Dermatologist Emma Guttman, MD, PhD
March 10, 2025
AAD 2025. Guttman, among the world's foremost researchers in dermatology, toplined how far the field has come in her "Hot Topics" presentation on the final day of the 2025 AAD.
Delgocitinib Data Reveal "Super Responders" in CHE During AAD 2025 Late Breaker
March 10, 2025
Data on delgocitinib from the DELTA development program highlight efficacy of the topical JAK inhibitor for treatment of chronic hand eczema.
Brian S. Kim, MD: Why Primary Care Clinicians Should Prescribe New Treatments for Atopic Dermatitis
March 10, 2025
Brian S. Kim, MD, a worldwide leader in research into itch and other skin conditions, says the safety profile and ease of use of new treatments for AD mean primary care clinicians should definitely consider prescribing them.
The Link Between Itch and Aging, with Daniel Butler, MD
March 10, 2025
Daniel Butler, MD, discusses a more complex definition of immunosenescence, and the interplay between aging and itch-related conditions.
Daniel Butler, MD: Pearls for Primary Care When Treating and Referring Older Adults for Chronic Itch
March 09, 2025
Butler addresses how primary care can help manage the burdens of itch in their older patients and offers pearls for consulting and referring to dermatology.
Rocatinlimab, an OX40 Inhibitor, Achieves Positive Results in Atopic Dermatitis Treatment: ROCKET-Horizon Topline Findings
March 09, 2025
Approximately one-third of participants treated with rocatinlimab achieved EASI-75 at 24 weeks, more than 2 times the proportion in the placebo group, among other robust findings.
Dupilumab Demonstrates Superior Long-Term Persistence Over Upadacitinib and Tralokinumab in Atopic Dermatitis
March 09, 2025
Dupilumab was associated with the highest drug survival in monotherapy with nearly 90% of study participants remaining on treatment at both 12 and 24 months.
Atopic Dermatitis: It’s Not the Food, I Promise You
March 08, 2025
AAD 2025. Peter Lio, MD, from the Feinberg School of Medicine in Chicago, says, skip the elimination diet because food is rarely a cause of atopic dermatitis.
Rocatinlimab Shows Significant Efficacy in Moderate to Severe Atopic Dermatitis: Phase 3 IGNITE Trial Results
March 08, 2025
AAD 2025: The IGNITE study of the OX40 inhibitor included adults previously treated with a biologic or systemic JAK inhibitor, according to Amgen and Kyowa Kirin.